Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
231 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Psoriatic Arthritis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Pipeline Review, H2 2016, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape. Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 9, 8, 10, 2, 15, 7 and 2 respectively.Psoriatic Arthritis. Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis (Musculoskeletal Disorders). - The pipeline guide reviews pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Psoriatic Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Psoriatic Arthritis Overview 8 Therapeutics Development 9 Pipeline Products for Psoriatic Arthritis - Overview 9 Pipeline Products for Psoriatic Arthritis - Comparative Analysis 10 Psoriatic Arthritis - Therapeutics under Development by Companies 11 Psoriatic Arthritis - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Psoriatic Arthritis - Products under Development by Companies 18 Psoriatic Arthritis - Companies Involved in Therapeutics Development 22 3SBio Inc. 22 AbbVie Inc 23 AbGenomics International, Inc. 24 Alteogen Inc. 25 Amgen Inc. 26 Biocon Limited 27 Bionovis SA 28 Bristol-Myers Squibb Company 29 Celgene Corporation 30 Coherus BioSciences, Inc. 31 Eli Lilly and Company 32 Forward Pharma A/S 33 Genor BioPharma Co Ltd 34 Innovent Biologics, Inc. 35 Johnson & Johnson 36 Kadmon Corporation, LLC 37 KPI Therapeutics, Inc. 38 Momenta Pharmaceuticals, Inc. 39 Morphotek, Inc. 40 Mycenax Biotech Inc. 41 NeuClone Pty Ltd 42 Novo Nordisk A/S 43 Oncobiologics, Inc. 44 Pfizer Inc. 45 Prothena Corporation Plc 46 Reliance Life Sciences Pvt. Ltd. 47 Sandoz International GmbH 48 Therapeutic Proteins International, LLC 49 UCB SA 50 Valeant Pharmaceuticals International, Inc. 51 Vitae Pharmaceuticals, Inc. 52 Vitaeris Inc 53 Xbrane Biopharma AB 54 Psoriatic Arthritis - Therapeutics Assessment 55 Assessment by Monotherapy Products 55 Assessment by Target 56 Assessment by Mechanism of Action 59 Assessment by Route of Administration 62 Assessment by Molecule Type 64 Drug Profiles 66 abatacept - Drug Profile 66 AbGn-168H - Drug Profile 71 ABT-122 - Drug Profile 73 adalimumab biosimilar - Drug Profile 75 adalimumab biosimilar - Drug Profile 77 adalimumab biosimilar - Drug Profile 78 adalimumab biosimilar - Drug Profile 79 adalimumab biosimilar - Drug Profile 80 adalimumab biosimilar - Drug Profile 81 adalimumab biosimilar - Drug Profile 82 adalimumab biosimilar - Drug Profile 84 adalimumab biosimilar - Drug Profile 86 adalimumab biosimilar - Drug Profile 87 adalimumab biosimilar - Drug Profile 88 adalimumab biosimilar - Drug Profile 89 adalimumab biosimilar - Drug Profile 90 adalimumab biosimilar - Drug Profile 91 apremilast - Drug Profile 92 apremilast - Drug Profile 103 bimekizumab - Drug Profile 104 certolizumab pegol biosimilar - Drug Profile 106 clazakizumab - Drug Profile 107 dalazatide - Drug Profile 111 dimethyl fumarate - Drug Profile 116 DNX-114 - Drug Profile 118 DNX-514 - Drug Profile 119 Drug to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile 120 etanercept - Drug Profile 121 etanercept biosimilar - Drug Profile 123 etanercept biosimilar - Drug Profile 124 etanercept biosimilar - Drug Profile 125 etanercept biosimilar - Drug Profile 126 etanercept biosimilar - Drug Profile 127 etanercept biosimilar - Drug Profile 130 etanercept biosimilar - Drug Profile 131 golimumab - Drug Profile 133 golimumab biosimilar - Drug Profile 141 golimumab biosimilar - Drug Profile 142 guselkumab - Drug Profile 143 infliximab biosimilar - Drug Profile 147 infliximab biosimilar - Drug Profile 148 infliximab biosimilar - Drug Profile 149 infliximab biosimilar - Drug Profile 152 infliximab biosimilar - Drug Profile 153 infliximab biosimilar - Drug Profile 156 infliximab biosimilar - Drug Profile 157 INV-17 - Drug Profile 158 itolizumab - Drug Profile 159 ixekizumab - Drug Profile 161 KANAb-071 - Drug Profile 167 KD-025 - Drug Profile 168 liraglutide - Drug Profile 172 PRX-003 - Drug Profile 179 risankizumab - Drug Profile 181 tofacitinib citrate - Drug Profile 184 upadacitinib tartrate - Drug Profile 197 ustekinumab biosimilar - Drug Profile 199 ustekinumab biosimilar - Drug Profile 200 VALBRO-03 - Drug Profile 201 VTP-43742 - Drug Profile 202 Psoriatic Arthritis - Dormant Projects 205 Psoriatic Arthritis - Discontinued Products 207 Psoriatic Arthritis - Product Development Milestones 208 Featured News & Press Releases 208 Appendix 225 Methodology 225 Coverage 225 Secondary Research 225 Primary Research 225 Expert Panel Validation 225 Contact Us 225 Disclaimer 226
List of Tables
Number of Products under Development for Psoriatic Arthritis, H2 2016 14 Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H2 2016 15 Number of Products under Development by Companies, H2 2016 17 Number of Products under Development by Companies, H2 2016 (Contd..1) 18 Comparative Analysis by Late Stage Development, H2 2016 19 Comparative Analysis by Clinical Stage Development, H2 2016 20 Comparative Analysis by Early Stage Development, H2 2016 21 Comparative Analysis by Unknown Stage Development, H2 2016 22 Products under Development by Companies, H2 2016 23 Products under Development by Companies, H2 2016 (Contd..1) 24 Products under Development by Companies, H2 2016 (Contd..2) 25 Products under Development by Companies, H2 2016 (Contd..3) 26 Psoriatic Arthritis - Pipeline by 3SBio Inc., H2 2016 27 Psoriatic Arthritis - Pipeline by AbbVie Inc, H2 2016 28 Psoriatic Arthritis - Pipeline by AbGenomics International, Inc., H2 2016 29 Psoriatic Arthritis - Pipeline by Alteogen Inc., H2 2016 30 Psoriatic Arthritis - Pipeline by Amgen Inc., H2 2016 31 Psoriatic Arthritis - Pipeline by Biocon Limited, H2 2016 32 Psoriatic Arthritis - Pipeline by Bionovis SA, H2 2016 33 Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Company, H2 2016 34 Psoriatic Arthritis - Pipeline by Celgene Corporation, H2 2016 35 Psoriatic Arthritis - Pipeline by Coherus BioSciences, Inc., H2 2016 36 Psoriatic Arthritis - Pipeline by Eli Lilly and Company, H2 2016 37 Psoriatic Arthritis - Pipeline by Forward Pharma A/S, H2 2016 38 Psoriatic Arthritis - Pipeline by Genor BioPharma Co Ltd, H2 2016 39 Psoriatic Arthritis - Pipeline by Innovent Biologics, Inc., H2 2016 40 Psoriatic Arthritis - Pipeline by Johnson & Johnson, H2 2016 41 Psoriatic Arthritis - Pipeline by Kadmon Corporation, LLC, H2 2016 42 Psoriatic Arthritis - Pipeline by KPI Therapeutics, Inc., H2 2016 43 Psoriatic Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 44 Psoriatic Arthritis - Pipeline by Morphotek, Inc., H2 2016 45 Psoriatic Arthritis - Pipeline by Mycenax Biotech Inc., H2 2016 46 Psoriatic Arthritis - Pipeline by NeuClone Pty Ltd, H2 2016 47 Psoriatic Arthritis - Pipeline by Novo Nordisk A/S, H2 2016 48 Psoriatic Arthritis - Pipeline by Oncobiologics, Inc., H2 2016 49 Psoriatic Arthritis - Pipeline by Pfizer Inc., H2 2016 50 Psoriatic Arthritis - Pipeline by Prothena Corporation Plc, H2 2016 51 Psoriatic Arthritis - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2016 52 Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H2 2016 53 Psoriatic Arthritis - Pipeline by Therapeutic Proteins International, LLC, H2 2016 54 Psoriatic Arthritis - Pipeline by UCB SA, H2 2016 55 Psoriatic Arthritis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 56 Psoriatic Arthritis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016 57 Psoriatic Arthritis - Pipeline by Vitaeris Inc, H2 2016 58 Psoriatic Arthritis - Pipeline by Xbrane Biopharma AB, H2 2016 59 Assessment by Monotherapy Products, H2 2016 60 Number of Products by Stage and Target, H2 2016 62 Number of Products by Stage and Mechanism of Action, H2 2016 65 Number of Products by Stage and Route of Administration, H2 2016 68 Number of Products by Stage and Molecule Type, H2 2016 70 Psoriatic Arthritis - Dormant Projects, H2 2016 210 Psoriatic Arthritis - Dormant Projects (Contd..1), H2 2016 211 Psoriatic Arthritis - Discontinued Products, H2 2016 212
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
